CTSO - Cytosorbents Crp - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

CTSO is currently covered by 3 analysts with an average price target of $5.74. This is a potential upside of $4.66 (431.48%) from yesterday's end of day stock price of $1.08.

Cytosorbents Crp's activity chart (see below) currently has 18 price targets and 35 ratings on display. The stock rating distribution of CTSO is 71.43% BUY and 28.57% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 20% with an average time for these price targets to be met of 82.8 days.

Highest price target for CTSO is $10, Lowest price target is $1, average price target is $5.

Most recent stock forecast was given by JASON KOLBERT from BENCHMARK on 21-Jul-2025. First documented stock forecast 07-Oct-2016.

Best performing analysts who are covering CTSO - Cytosorbents Crp:

Andrew D'silva Sean Lee John Walsh Joshua Jennings Jason Kolbert

Currently out of the existing stock ratings of CTSO, 15 are a BUY (71.43%), 6 are a HOLD (28.57%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$10

$8.84 (762.07%)

$10

29 days ago
(21-Jul-2025)

0/9 (0%)

$8.96 (861.54%)

Hold

$1

$-0.16 (-13.79%)

$1

3 months 4 days ago
(15-May-2025)

6/10 (60%)

$0.17 (20.48%)

20

Buy

$4

$3.02 (308.16%)

$6

1 years 11 months 12 days ago
(07-Sep-2023)

0/4 (0%)

$1.66 (70.94%)

Buy

$10

$8.3 (488.24%)

3 years 10 months 7 days ago
(13-Oct-2021)

0/1 (0%)

$3.87 (63.13%)

Buy

$17

$15.84 (1365.52%)

$16

4 years 7 months 15 days ago
(04-Jan-2021)

2/5 (40%)

$8.63 (103.11%)

394

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is CTSO (Cytosorbents Crp) average time for price targets to be met?

On average it took 82.8 days on average for the stock forecasts to be realized with a an average price target met ratio 20

Which analyst has the current highest performing score on CTSO (Cytosorbents Crp) with a proven track record?

ANDREW D'SILVA

Which analyst has the current lower performing score on CTSO (Cytosorbents Crp) with a proven track record?

JASON KOLBERT

Which analyst has the most public recommendations on CTSO (Cytosorbents Crp)?

Andrew D'silva has 6 price targets and 5 ratings on CTSO

Which analyst is the currently most bullish on CTSO (Cytosorbents Crp)?

Andrew D'silva with highest potential upside - $15.84

Which analyst is the currently most reserved on CTSO (Cytosorbents Crp)?

Sean Lee with lowest potential downside - -$0.16

Cytosorbents Crp in the News

Cytosorbents outlines DrugSorb ATR regulatory appeals and targets core business breakeven as German reorganization drives 22% sales growth

Earnings Call Insights: Cytosorbents Corporation (CTSO) Q2 2025 MANAGEMENT VIEW * CEO Phillip P. Chan introduced Cytosorbents as a leader in blood purification for critical care and cardiac surgery, emphasizing that CytoSorb, the flagship product, is “the anchor of our core international business with over — with nearly 300,000 devices utilized to date in more...

CytoSorbents Corp (NASDAQ:CTSO) Reports Mixed Q2 2025 Earnings with Revenue Beat and Narrower Loss

CytoSorbents Corp (NASDAQ:CTSO [https://www.chartmill.com/stock/quote/CTSO]) reported its second-quarter 2025 financial results, delivering mixed performance relative to analyst expectations. The company, which specializes in blood purification technologies for critical care, posted revenue of $9.62 million, slightly above the consensus estimate of $9.42 million. Earnings per share (EPS) came in at -$0.05, marginally better than the anticipated -$0.051....

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?